All In Biotech

Drug Trial Radar · NCT04856904

Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

Evaluation of the Risk of Atrophic Acne Scar Formation During Treatment of Acne Vulgaris Subjects With Trifarotene 50 μg/g Cream Versus Vehicle Cream Over 24 Weeks

Last checked: Nov 20, 2026Latest source record: Jun 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

121

Actual

Start

May 28, 2021

Primary completion

Feb 8, 2023

Study completion Jun 30, 2023

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Apr 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 17 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.

Conditions

  • Acne Vulgaris

Interventions

  • Trifarotene CreamDrug

    Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks

  • Trifarotene Vehicle CreamDrug

    Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half Face at Week 24Time frame: Baseline, Week 24

Locations

18 sites in 3 countries. Site status is shown where the registry gives one.

  • Galderma Investigational Site #8873

    Scottsdale, Arizona

  • Galderma Investigational Site #8447

    Fort Smith, Arkansas

  • Galderma Investigational Site #8608

    Santa Monica, California

  • Galderma Investigational Site #9928

    Boynton Beach, Florida

  • Galderma Investigational Site #8295

    Miami, Florida

  • Galderma Investigational Site #8883

    Miramar, Florida

  • Galderma Investigational Site #8189

    Snellville, Georgia

  • Galderma Investigational Site #8367

    Arlington Heights, Illinois

  • Galderma Investigational Site #8838

    Darien, Illinois

  • Galderma Investigational Site #8601

    Metairie, Louisiana

  • Galderma Investigational Site #9936

    New Orleans, Louisiana

  • Galderma Investigational Site #8108

    Las Vegas, Nevada

  • Galderma Investigational Site #8881

    Stony Brook, New York

  • Galderma Investigational Site #8886

    Sugarloaf, Pennsylvania

  • Galderma Investigational Site #9920

    Arlington, Texas

  • Galderma Investigational Site #9918

    Peterborough, Ontario, Canada

  • Galderma Investigational Site #9927

    Saint-Jérôme, Quebec, Canada

  • Galderma Investigational Site #6167

    Nantes, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.